Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
5 augusti, 21:16
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
PR Newswire
PHILADELPHIA, Aug. 5, 2025
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S ( NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark , after a class action lawsuit was filed against Novo.
Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
On July 29, 2025, Novo lowered its sales and profit guidance for the second half of fiscal 2025, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for both Wegovy® and Ozempic®.
In reaction, Novo's stock price plunged from $69.00 to $53.94 per share, a one-day decline of more than 21%.
If you are a Novo investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague : Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague , with offices in Philadelphia , Minneapolis , Delaware , Washington, D.C. , San Diego , San Francisco , Chicago , Malvern, PA , and Toronto , has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States .
For more information or to discuss your rights, please contact:
Andrew Abramowitz , Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
SOURCE Berger Montague
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
5 augusti, 21:16
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
PR Newswire
PHILADELPHIA, Aug. 5, 2025
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S ( NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark , after a class action lawsuit was filed against Novo.
Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
On July 29, 2025, Novo lowered its sales and profit guidance for the second half of fiscal 2025, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for both Wegovy® and Ozempic®.
In reaction, Novo's stock price plunged from $69.00 to $53.94 per share, a one-day decline of more than 21%.
If you are a Novo investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague : Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague , with offices in Philadelphia , Minneapolis , Delaware , Washington, D.C. , San Diego , San Francisco , Chicago , Malvern, PA , and Toronto , has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States .
For more information or to discuss your rights, please contact:
Andrew Abramowitz , Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
SOURCE Berger Montague
Fonder
Konjunktur
Novo Nordisk
Aktieråd
-992x558.webp&w=3840&q=75)
Analys
Fonder
Konjunktur
Novo Nordisk
Aktieråd
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
